Patents by Inventor Gillian A. Kingsbury
Gillian A. Kingsbury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220289858Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.Type: ApplicationFiled: October 7, 2021Publication date: September 15, 2022Inventors: Lorenzo Benatuil, Maria A. Argiriadi, Bradford L. Mcrae, Chung-Ming Hsieh, David A. Egan, John E. Harlan, Russell A. Judge, Rui Wang, Gillian A. Kingsbury
-
Publication number: 20190359725Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.Type: ApplicationFiled: December 21, 2018Publication date: November 28, 2019Inventors: Lorenzo Benatuil, Maria A. Argiriadi, Bradford L. McRae, Chung-Ming Hsieh, David A. Egan, John E. Harlan, Russell A. Judge, Rui Wang, Gillian A. Kingsbury
-
Publication number: 20160319026Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: April 5, 2016Publication date: November 3, 2016Inventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-Lappe, Jijie Gu
-
Patent number: 9029508Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: April 28, 2009Date of Patent: May 12, 2015Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
-
Publication number: 20150104452Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: June 10, 2014Publication date: April 16, 2015Inventors: Tariq Ghayur, Edward B. Reilly, Andrew Phillips, Randy L. Bell, Yingchun Li, Hua Ying, Susan E. Morgan-Lappe, Gillian A. Kingsbury, Jieyi Wang, Suzanne M. Norvell, Junjian Liu
-
Publication number: 20150017168Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: July 15, 2014Publication date: January 15, 2015Applicant: ABBVIE INC.Inventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-Lappe
-
Patent number: 8444987Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.Type: GrantFiled: May 26, 2011Date of Patent: May 21, 2013Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gillian A. Kingsbury, Kevin R. Leiby
-
NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES
Publication number: 20120270219Abstract: The invention provides isolated TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: July 2, 2012Publication date: October 25, 2012Applicant: Millennium Pharmaceuticals, Inc.Inventors: Douglas A. Holtzman, John D. Sharp, Kevin R. Leiby, Steven Bossone, Yang Pan, Thomas M. Barnes, Christopher C. Fraser, Nicholas Wrighton, Paul S. Myers, Gillian Kingsbury -
Publication number: 20120148573Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.Type: ApplicationFiled: May 26, 2011Publication date: June 14, 2012Applicant: Millennium Pharmaceuticals, Inc.Inventors: Gillian A. Kingsbury, Kevin R. Leiby
-
Patent number: 8163503Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: May 20, 2010Date of Patent: April 24, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventor: Gillian Kingsbury
-
Publication number: 20110263827Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: April 30, 2010Publication date: October 27, 2011Applicant: Abbott LaboratoriesInventors: Tariq Ghayur, Junjian Liu, Gillian A. Kingsbury, Edward B. Reilly, Susan E. Morgan-lappe
-
Patent number: 7972797Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.Type: GrantFiled: September 24, 2008Date of Patent: July 5, 2011Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gillian A. Kingsbury, Kevin R. Leiby
-
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
Publication number: 20110065124Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: May 20, 2010Publication date: March 17, 2011Inventors: Douglas A. Holtzman, John D. Sharp, Kevin R. Leiby, Steven Bossone, Yang Pan, Thomas M. Barnes, Christopher C. Fraser, Nicholas Wrighton, Paul S. Myers, Gillian Kingsbury -
Publication number: 20100260668Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: October 23, 2009Publication date: October 14, 2010Applicant: ABBOTT LABORATORIESInventors: Tariq Ghayur, Susan E. Morgan-lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying, Zhihong Liu
-
Publication number: 20100076178Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: April 28, 2009Publication date: March 25, 2010Applicant: ABBOTT LABORATORIESInventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
-
Publication number: 20090304703Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.Type: ApplicationFiled: September 24, 2008Publication date: December 10, 2009Applicant: Millennium Pharmaceuticals, Inc.Inventors: Gillian A. Kingsbury, Kevin R. Leiby
-
Patent number: 7452980Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.Type: GrantFiled: November 14, 2006Date of Patent: November 18, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gillian A. Kingsbury, Kevin R. Leiby
-
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
Publication number: 20080213778Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: November 8, 2007Publication date: September 4, 2008Inventors: Douglas A. Holtzman, John D. Sharp, Kevin R. Leiby, Steven Bossone, Yang Pan, Thomas M. Barnes, Christopher C. Fraser, Nicholas Wrighton, Paul S. Myers, Gillian Kingsbury -
Patent number: 7385036Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 23, 2005Date of Patent: June 10, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventor: Gillian Kingsbury
-
Publication number: 20070059303Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders. In this regard, the invention provides methods for the identification and therapeutic use of compounds for treatments of immune disorders, especially TH cell subpopulation-related disorders and including TH2 and TH2-like disorders (i.e.Type: ApplicationFiled: November 14, 2006Publication date: March 15, 2007Inventors: Gillian Kingsbury, Kevin Leiby